Caroline Loew - 14 Dec 2023 Form 4/A Insider Report for Mural Oncology plc (MURA)

Role
Chief Executive Officer, Director
Signature
/s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew
Issuer symbol
MURA
Transactions as of
14 Dec 2023
Net transactions value
$0
Form type
4/A
Filing time
11 Apr 2024, 21:10:41 UTC
Date Of Original Report
18 Dec 2023
Previous filing
07 Nov 2023
Next filing
04 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MURA Stock Option (right to buy) Award +379,690 379,690 14 Dec 2023 Ordinary Shares 379,690 $5.48 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment to Form 4 is being filed solely to correct the exercise price of the granted option, which was previously reported as being $3.61 due to a scrivener's error.
F2 Represents an option award originally granted by Alkermes plc ("Alkermes") that was converted into an option award of Mural Oncology plc (the "Issuer") in connection with the spin-off of the Issuer from Alkermes.
F3 This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 5, 2023, subject to the reporting person's continued service with the Issuer.